Concepedia

Gracy Zacharian

GZ

Statistics

Publications

3

Citations

426

H-Index

3

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Gracy Zacharian is an author at The University of Texas MD Anderson Cancer Center specializing in immunotherapy, rituximab-based therapy, and chronic lymphocytic leukemia therapy.

Publications per year

2012–2014

3

Publications

3

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Jan A. Burger, Michael J. Keating, William G. Wierda et al. · The Lancet Oncology · 2014 · 332 citations

, , +14

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, Michael J. Keating, William G. Wierda et al. · Blood · 2012 · 52 citations

, , +16

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Jan A. Burger, Michael J. Keating, William G. Wierda et al. · Blood · 2013 · 42 citations

, , +13

1–3 of 3